진행성 위선암 환자에서 Etoposide, Doxorubicin, Cisplatine(EAP) 복합 화학요법의 효과
Etoposide, Adriamycin, Cisplatin(EAP) Combination Chemotherapy for Advanced Gastric Cancer
대한암학회지 1992년 24권 4호 p.562 ~ 569
소속 상세정보
김준식
김정희/어완규/김시영/윤휘중/조경삼
KMID : 0360319920240040562
Abstract
Recently, Etoposide, Adriamycin and Cisplatin(EAP) combination chemotherapy is widely used in patients with advanced gastric cancer. Response rates of more than 50% were reported with this combination by Preusser.
Forty-one patients with metastatic or nonresectable gastric cancer received etoposide, 10mg/m* IV, day4-6; adriamycin, 20mg/m* IV, days 1 and 7; cisplatin, 40mg/m* IV, days 2 and 8. Cycles were repeated every 4 weeks. Response rate, survival rate
and
toxicity were evaluated.
@ES Results were as following;
@EN 1) the total 41 patients received EAP chemotherapy. Twenty-four patients were evaluated. The eighty eight cycles of chemotherapy were administered(mean, 3.7 cycles per patient; range, 2-8 cycles)
2) Of the sixteen patients with measurable disease, none had complete remission and 3(18.8%) achieved parital remission, resulting in an overall response rate of 18.8%. There were seven stable disease and six progressive disease.
3) The overall median survival was 25 weeks(7-68 wks) and the median time to progression was 16 weeks.
4) Main toxicities were leukopenia and thrombocytopenia. 16% of patients developed grade 3 to 4 myelosuppression and 4% developed severe infections. Nonhematologic toxicites such as nausea, vomiting and alopecia appear in all cases, but
toxicities
of
WHO grade 4 were not observed. Neurologic toxicity and renal insufficiency. Who grade 1 were observed in 37% and 17% of patients.
In view of this low response rate, low survival rate and toxicity, this combination as a palliative therapy of advanced gastric cancer is not justified.
키워드
원문 및 링크아웃 정보
등재저널 정보